WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 577820
CAS#: 275375-69-4
Description: BMS-223131 is a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels. BMS-223131 effectively reduced stress-induced colonic motility and visceral nociception supporting the potential utility of maxi-K channel openers for the treatment of bowel disorders involving dysfunctional motility and visceral sensitivity.
MedKoo Cat#: 577820
Name: BMS-223131
CAS#: 275375-69-4
Chemical Formula: C18H13ClF3NO3
Exact Mass: 383.0536
Molecular Weight: 383.7512
Elemental Analysis: C, 56.34; H, 3.41; Cl, 9.24; F, 14.85; N, 3.65; O, 12.51
Synonym: BMS-223131; BMS 223131; BMS223131
IUPAC/Chemical Name: 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one
InChi Key: QESHSZWKJULSAR-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H13ClF3NO3/c19-10-2-4-15(25)13(8-10)16-11(5-6-24)17(26)23-14-3-1-9(7-12(14)16)18(20,21)22/h1-4,7-8,24-25H,5-6H2,(H,23,26)
SMILES Code: C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | BMS-223131 is a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels. |
| In vitro activity: | TBD |
| In vivo activity: | BMS-223131 (2, 6, or 20 mg/kg i.p.) produced a small but dose-dependent and significant reduction in cumulative 24-h fecal output. Fecal output in response to stress (1-h restraint plus bursts of air to the face) was markedly inhibited by BMS-223131, and moisture content was significantly reduced. With regard to visceral pain, the transient and distention-dependent reduction in arterial pressure in anesthetized animals was inhibited by BMS-223131 in a dose-dependent manner. Distension-induced abdominal withdrawal in conscious rats was also dose-dependently attenuated by BMS-223131. Reference: J Pharmacol Exp Ther. 2005 May;313(2):840-7. https://pubmed.ncbi.nlm.nih.gov/15701710/ |
The following data is based on the product molecular weight 383.7512 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | Sivarao DV, Newberry K, Langdon S, Lee AV, Hewawasam P, Plym MJ, Signor L, Myers R, Lodge NJ. Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception. J Pharmacol Exp Ther. 2005 May;313(2):840-7. doi: 10.1124/jpet.104.079285. Epub 2005 Feb 8. Erratum in: J Pharmacol Exp Ther. 2005 Oct;315(1):476. PMID: 15701710. |
| In vitro protocol: | TBD |
| In vivo protocol: | Sivarao DV, Newberry K, Langdon S, Lee AV, Hewawasam P, Plym MJ, Signor L, Myers R, Lodge NJ. Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception. J Pharmacol Exp Ther. 2005 May;313(2):840-7. doi: 10.1124/jpet.104.079285. Epub 2005 Feb 8. Erratum in: J Pharmacol Exp Ther. 2005 Oct;315(1):476. PMID: 15701710. |
1. Sivarao DV, Newberry K, Langdon S, Lee AV, Hewawasam P, Plym MJ, Signor L, Myers R, Lodge NJ. Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception. J Pharmacol Exp Ther. 2005 May;313(2):840-7. doi: 10.1124/jpet.104.079285. Epub 2005 Feb 8. Erratum in: J Pharmacol Exp Ther. 2005 Oct;315(1):476. PMID: 15701710.
